002252 上海莱士
已收盘 06-10 15:00:00
资讯
新帖
简况
上海莱士：血液制品行业需求刚性、长期增长逻辑清晰
证券之星 · 11:33
上海莱士：血液制品行业需求刚性、长期增长逻辑清晰
上海莱士：2025年高管薪酬总额同比降幅超40%
证券之星 · 11:33
上海莱士：2025年高管薪酬总额同比降幅超40%
上海莱士：截至2026年5月29日，公司股东总户数为115,062户
证券之星 · 11:30
上海莱士：截至2026年5月29日，公司股东总户数为115,062户
6月9日上海莱士现553.61万元大宗交易
证券之星 · 06-09 17:41
6月9日上海莱士现553.61万元大宗交易
上海莱士：目前，公司采浆增速与行业情况相当
证券之星 · 06-05
上海莱士：目前，公司采浆增速与行业情况相当
上海莱士：已依规制定市值管理制度
证券之星 · 05-27
上海莱士：已依规制定市值管理制度
5月25日上海莱士发生1笔大宗交易 成交金额1221.64万元
证券之星 · 05-25
5月25日上海莱士发生1笔大宗交易 成交金额1221.64万元
5月22日上海莱士创60日新低，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 05-22
5月22日上海莱士创60日新低，招商国证生物医药指数(LOF)C基金重仓该股
上海莱士：不存在重大潜在爆雷风险
中金财经 · 05-19
上海莱士：不存在重大潜在爆雷风险
上海莱士：2025年全年采浆量超过2,000吨
证券之星 · 05-19
上海莱士：2025年全年采浆量超过2,000吨
上海莱士：SR604针对血友病A/B及先天性凝血因子Ⅶ缺乏症适应症已完成中期数据统计
证券之星 · 05-19
上海莱士：SR604针对血友病A/B及先天性凝血因子Ⅶ缺乏症适应症已完成中期数据统计
上海莱士：董事王全立先生由控股股东海盈康提名
证券之星 · 05-19
上海莱士：董事王全立先生由控股股东海盈康提名
上海莱士：SR604抗体基于海外转让的小鼠杂交瘤细胞株开发
证券之星 · 05-19
上海莱士：SR604抗体基于海外转让的小鼠杂交瘤细胞株开发
股市必读：上海莱士(002252)股东户数11.48万户，较上期增加0.13%
证券之星 · 05-18
股市必读：上海莱士(002252)股东户数11.48万户，较上期增加0.13%
上海莱士（002252）披露第二期员工持股计划（草案），5月15日股价下跌1.27%
证券之星 · 05-15
上海莱士（002252）披露第二期员工持股计划（草案），5月15日股价下跌1.27%
上海莱士：截至2026年5月8日，公司股东总户数为114,819户
证券之星 · 05-15
上海莱士：截至2026年5月8日，公司股东总户数为114,819户
上海莱士：SR604人源化活化蛋白C单抗是在海外转让的杂交瘤细胞株基础上进一步研究开发的产品
证券之星 · 05-15
上海莱士：SR604人源化活化蛋白C单抗是在海外转让的杂交瘤细胞株基础上进一步研究开发的产品
股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.31%
中金财经 · 05-08
股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.31%
券商重仓路径曝光：去年单股最高持仓超百亿，一季度新进百余股
第一财经 · 05-07
券商重仓路径曝光：去年单股最高持仓超百亿，一季度新进百余股
上海莱士(002252)4月30日股东户数11.47万户，较上期增加0.31%
证券之星 · 05-07
上海莱士(002252)4月30日股东户数11.47万户，较上期增加0.31%
加载更多
公司概况
公司名称：
上海莱士血液制品股份有限公司
所属行业：
医药制造业
上市日期：
2008-06-23
主营业务：
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。
发行价格：
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":5.01,"timestamp":1781074983000,"preClose":5.06,"halted":0,"volume":42772683,"delay":0,"changeRate":-0.0099,"floatShares":6588000000,"shares":6593000000,"eps":0.2013,"marketStatus":"已收盘","change":-0.05,"latestTime":"06-10 15:00:00","open":5.04,"high":5.08,"low":4.98,"amount":214000000,"amplitude":0.0198,"askPrice":5.02,"askSize":2169,"bidPrice":5.01,"bidSize":1692,"shortable":0,"etf":0,"ttmEps":0.2013,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781141400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.06,"symbolType":"stock","openAndCloseTimeList":[[1781055000000,1781062200000],[1781067600000,1781074800000]],"highLimit":5.57,"lowLimit":4.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6592672885,"isCdr":false,"pbRate":1.03,"roa":"--","peRate":24.888227,"roe":"0.97%","epsLYR":0.24,"committee":0.08516,"marketValue":33029000000,"turnoverRate":0.0065,"status":1,"floatMarketCap":33006000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2642744414","title":"上海莱士：血液制品行业需求刚性、长期增长逻辑清晰","url":"https://stock-news.laohu8.com/highlight/detail?id=2642744414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642744414?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:33","pubTimestamp":1781062414,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士06月09日在投资者关系平台上答复投资者关心的问题。血液制品行业需求刚性、长期增长逻辑清晰。公司作为国内血液制品龙头企业，拥有稳定浆站资源、完整产品管线、成熟生产质控体系，同时积极布局创新药研发，中长期成长基础扎实。公司将持续做精主业、加快研发转化、优化股东回报，并保持常态化投资者沟通，以稳健经营和扎实业绩回报广大长期投资者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000017293.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0188","BK0046","BK0239","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642147204","title":"上海莱士：2025年高管薪酬总额同比降幅超40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642147204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642147204?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:33","pubTimestamp":1781062396,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士06月09日在投资者关系平台上答复投资者关心的问题。公司如何改变现状上海莱士回复：感谢您的关注！公司高度重视投资者合理回报，近几年已通过提高分红频次等方式积极回馈股东。公司高管薪酬严格与业绩挂钩、动态调整，2025年高管薪酬总额同比降幅超40%；叠加高管参与第二期员工持股且以高管身份参与计划的高管还承诺放弃2026-2028年部分薪酬，利益与公司深度绑定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000017278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0239","BK0196","BK0046","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642241474","title":"上海莱士：截至2026年5月29日，公司股东总户数为115,062户","url":"https://stock-news.laohu8.com/highlight/detail?id=2642241474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642241474?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:30","pubTimestamp":1781062251,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止5月31号，公司的股东人数是多少？谢谢上海莱士回复：感谢您的关注！截至2026年5月29日，公司股东总户数为115,062户。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000017149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0196","BK0028","002252","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642664564","title":"6月9日上海莱士现553.61万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2642664564","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642664564?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:41","pubTimestamp":1780998111,"startTime":"0","endTime":"0","summary":"证券之星消息，6月9日上海莱士发生大宗交易，交易数据如下：大宗交易成交价格5.56元，相对当日收盘价溢价9.88%，成交99.57万股，成交金额553.61万元，买方营业部为中信建投证券股份有限公司郑州经三北路证券营业部，卖方营业部为国金证券股份有限公司上海静安区南京西路证券营业部。截至2026年6月9日收盘，上海莱士报收于5.06元，下跌0.78%，换手率0.44%，成交量28.83万手，成交额1.46亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900028800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","002252","BK0188","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641019173","title":"上海莱士：目前，公司采浆增速与行业情况相当","url":"https://stock-news.laohu8.com/highlight/detail?id=2641019173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641019173?lang=zh_cn&edition=full","pubTime":"2026-06-05 11:34","pubTimestamp":1780630473,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问：血制品行业采浆增速下降，但是莱士依然高于行业采浆，莱士这样做是要带动行业内卷吗？上海莱士回复：感谢您的关注。目前，公司采浆增速与行业情况相当，不存在无序扩采的情形，公司始终恪守行业良性发展原则，以合规经营提升自身价值回馈投资者。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500015260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002252","BK0239","BK0188","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688419","title":"上海莱士：已依规制定市值管理制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688419","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638688419?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:52","pubTimestamp":1779886363,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士05月26日在投资者关系平台上答复投资者关心的问题。公司高度重视股价表现与市值维护，已依规制定市值管理制度，坚持以提升经营质量为核心，持续夯实内在价值、增强投资价值与股东回报能力，切实维护全体股东利益。同时，公司推出了第二期员工持股计划、已回购股份注销事项，加强投资者关系管理，提升信息披露透明度，积极传递公司价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700043545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0196","BK0046","002252","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638539704","title":"5月25日上海莱士发生1笔大宗交易 成交金额1221.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638539704","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638539704?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:28","pubTimestamp":1779701294,"startTime":"0","endTime":"0","summary":"证券之星消息，5月25日上海莱士发生大宗交易，交易数据如下：大宗交易成交价格5.73元，相对当日收盘价溢价9.98%，成交213.2万股，成交金额1221.64万元，买方营业部为中信建投证券股份有限公司郑州经三北路证券营业部，卖方营业部为浙商证券股份有限公司郑州金水东路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2.13万手，溢价成交1笔。截至2026年5月25日收盘，上海莱士报收于5.21元，下跌0.38%，换手率0.46%，成交量30.62万手，成交额1.6亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0028","BK0196","BK0188","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637251394","title":"5月22日上海莱士创60日新低，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637251394","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637251394?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:38","pubTimestamp":1779439093,"startTime":"0","endTime":"0","summary":"证券之星消息，5月22日上海莱士创60日新低，收盘报5.23元，当日跌1.88%，换手率0.49%，成交量32.78万手，成交额1.72亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","BK0196","BK0028","BK0239","BK0188","161726","002252","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636888769","title":"上海莱士：不存在重大潜在爆雷风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2636888769","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636888769?lang=zh_cn&edition=full","pubTime":"2026-05-19 09:01","pubTimestamp":1779152509,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士05月18日在投资者关系平台上答复投资者关心的问题。二级市场股价受宏观环境、行业情绪、市场风格等多重因素影响。公司严格内控治理，持续规范经营、防范各类风险，不存在重大潜在爆雷风险。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/19/20260519892356.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/19/20260519892356.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260519/32235068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","BK0188","BK0028","BK0046","002252","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636145888","title":"上海莱士：2025年全年采浆量超过2,000吨","url":"https://stock-news.laohu8.com/highlight/detail?id=2636145888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636145888?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:57","pubTimestamp":1779152227,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士05月18日在投资者关系平台上答复投资者关心的问题。2）南岳生物并表后，2026年预计采浆量、产能利用率目标是多少？2025年全年采浆量超过2,000吨，同比增长超过8%，高于行业平均增幅，吨浆成本受原料、运营、浆站建设等多重因素综合影响，相关经营数据请以年报披露为准。南岳生物并入后，公司依托浆站整合、产能统筹提升整体运营效率，具体采浆情况请以定期报告披露为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0239","BK0188","002252","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636881488","title":"上海莱士：SR604针对血友病A/B及先天性凝血因子Ⅶ缺乏症适应症已完成中期数据统计","url":"https://stock-news.laohu8.com/highlight/detail?id=2636881488","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636881488?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:54","pubTimestamp":1779152046,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，关于互动平台回复的“SR604正在开展二期临床”，请核实：1）二期临床具体启动时间、预计完成时间？3）公司对SR604的商业化时间表、预计获批时间有无内部规划？公司分别于2025年02月14日、2025年07月09日、2025年11月05日披露了SR604注射液相关适应症进入二期临床的相关公告。公司将严格按照监管要求及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","002252","BK0239","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636888671","title":"上海莱士：董事王全立先生由控股股东海盈康提名","url":"https://stock-news.laohu8.com/highlight/detail?id=2636888671","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636888671?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:49","pubTimestamp":1779151748,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司董事王全立博士是哪个股东提名的？上海莱士回复：您好！感谢您的关注！董事王全立先生由控股股东海盈康提名。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002252","BK0188","BK0028","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636788860","title":"上海莱士：SR604抗体基于海外转让的小鼠杂交瘤细胞株开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2636788860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636788860?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:49","pubTimestamp":1779151748,"startTime":"0","endTime":"0","summary":"麻烦公司正面进一步解释此前回复中提及的海外原始杂交瘤细胞株相关说法。靶点是体内的活化蛋白C，SR604是针对这个靶点的抗体，该SR604抗体是在海外转让的针对活化蛋白C的小鼠杂交瘤细胞株产生的鼠抗人活化蛋白C抗体的基础上进一步研究开发的产品，该转让技术授权上海莱士对此杂交瘤细胞株的进一步研发以及用于中国大陆、中国香港地区及中国台湾地区的商业化用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0046","BK0196","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636585013","title":"股市必读：上海莱士(002252)股东户数11.48万户，较上期增加0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636585013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636585013?lang=zh_cn&edition=full","pubTime":"2026-05-18 01:29","pubTimestamp":1779038949,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，上海莱士报收于5.44元，下跌1.27%，换手率0.47%，成交量31.41万手，成交额1.72亿元。来自股本股东变化：截至5月8日股东户数增至11.48万户，户均持股量微降至5.78万股。股本股东变化股东户数变动近日上海莱士披露，截至2026年5月8日公司股东户数为11.48万户，较4月30日增加148.0户，增幅为0.13%。公司已履行现阶段必要的内部审议程序和信息披露义务，尚需召开股东会审议本次员工持股计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800000634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0188","BK0028","BK0196","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635038226","title":"上海莱士（002252）披露第二期员工持股计划（草案），5月15日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635038226","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635038226?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:13","pubTimestamp":1778854398,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，上海莱士报收于5.44元，较前一交易日下跌1.27%，最新总市值为361.11亿元。该股当日开盘5.51元，最高5.53元，最低5.42元，成交额达1.72亿元，换手率为0.47%。近日，上海莱士披露《第二期员工持股计划（草案）》。该计划尚需提交公司股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500043997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","BK0046","002252","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635779217","title":"上海莱士：截至2026年5月8日，公司股东总户数为114,819户","url":"https://stock-news.laohu8.com/highlight/detail?id=2635779217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635779217?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:36","pubTimestamp":1778816175,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士(002252)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问：截至2026年5月10日，公司股东总户数为多少户？上海莱士回复：您好！感谢您对我公司的关心和支持！ 截至2026年5月8日，公司股东总户数为114,819户。 谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500018855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","002252","BK0028","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635779135","title":"上海莱士：SR604人源化活化蛋白C单抗是在海外转让的杂交瘤细胞株基础上进一步研究开发的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2635779135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635779135?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:33","pubTimestamp":1778816000,"startTime":"0","endTime":"0","summary":"证券之星消息，上海莱士05月14日在投资者关系平台上答复投资者关心的问题。公司SR604人源化活化蛋白C单抗是在海外转让的杂交瘤细胞株基础上进一步研究开发的产品，该转让技术授权上海莱士SR604的进一步研发以及用于中国和香港台湾地区的商业化用途。全球其他海外市场的商业化权益，归属于本次技术合作的原海外授权方。如涉及重大事项，公司将严格依规及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500018567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252","BK0028","BK0046","BK0188","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633110986","title":"股市必读：上海莱士(002252)股东户数11.47万户，较上期增加0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633110986","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633110986?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:03","pubTimestamp":1778198602,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2026年5月7日收盘，上海莱士报收于5.56元，下跌0.18%，换手率0.4%，成交量26.58万手，成交额1.48亿元。资金流向5月7日主力资金净流入38.82万元；游资资金净流入1707.45万元；散户资金净流出1746.27万元。股东户数变动近日上海莱士披露，截至2026年4月30日公司股东户数为11.47万户，较4月20日增加360.0户，增幅为0.31%。户均持股数量由上期的5.81万股减少至5.79万股，户均持股市值为32.19万元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/08/20260508390859.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/08/20260508390859.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260508/32207637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","BK0188","BK0028","BK0046","002252","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128612","title":"券商重仓路径曝光：去年单股最高持仓超百亿，一季度新进百余股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128612","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633128612?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:42","pubTimestamp":1778157720,"startTime":"0","endTime":"0","summary":" “易中天”热度持续高涨，龙头券商也买进了前十大股东。 随着年报和一季报披露完毕，券商重仓路径浮现，在A股市场震荡上行中，哪些个股成为券商的“心头好”？ 第一财经根据Choice数据统计，截至去年年底，券商现身近300家A股公司的前十大流通股股东名单，合计持股总市值超700亿元。其中，截至去年年底，中信证券对中信建投的持仓市值超过百亿元。 随着一季报披露收官，券商最新调仓换股路径同步曝光。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-07/doc-inhxatff4721846.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-07/doc-inhxatff4721846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0198","LU1655091616.SGD","BK0127","300182","LU1794554557.SGD","LU2778985437.USD","BK0070","BK0056","LU2399975544.HKD","LU1961090484.USD","002714","SGXZ81163826.USD","BK0077","BK0132","603817","BK0155","BK0189","600566","BK0201","BK0195","601658","300532","LU1979443071.USD","BK0214","LU2495084118.USD","000670","002911","BK0125","BK0015","300502","BK0187","BK0197","LU0359202008.SGD","600863","601066","02714","BK0196","600919","002252","SGXZ49509284.SGD","BK0108","BK0239","600927","301314","BK0109","BK0182","000408","BK0046","BK0252","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111059","title":"上海莱士(002252)4月30日股东户数11.47万户，较上期增加0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111059","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633111059?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:29","pubTimestamp":1778146187,"startTime":"0","endTime":"0","summary":"证券之星消息，近日上海莱士披露，截至2026年4月30日公司股东户数为11.47万户，较4月20日增加360.0户，增幅为0.31%。在生物制品行业个股中，上海莱士股东户数高于行业平均水平，截至4月30日，生物制品行业平均股东户数为3.54万户。从股价来看，2026年4月20日至2026年4月30日，上海莱士区间跌幅为2.28%，在此期间股东户数增加360.0户，增幅为0.31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700028727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","002252","BK0188","BK0239","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781098190401,"stockEarnings":[{"period":"1week","weight":-0.0362},{"period":"1month","weight":-0.1092},{"period":"3month","weight":-0.193},{"period":"6month","weight":-0.2112},{"period":"1year","weight":-0.2698},{"period":"ytd","weight":-0.2}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0407},{"period":"3month","weight":-0.0299},{"period":"6month","weight":0.0353},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"115062人(较上一季度增加0.21%)","perCapita":"57255股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"659267万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}